FIELD: RSV antibody compositions.
SUBSTANCE: present invention is related to stable compositions containing antibodies or antigen-binding fragments thereof that bind to respiratory syncytial virus (RSV). Methods of preventing and/or treating RSV-related diseases using the compositions of the present invention are also provided.
EFFECT: invention provides formulations that contain a high concentration of antibody or antigen-binding fragment thereof and a viscosity level suitable for subcutaneous delivery, and do not result in high levels of aggregation.
20 cl, 15 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2775944C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| PHARMACEUTICAL FORMULA CONTAINING HUMAN ANTI-TSLP ANTIBODY | 2016 |
|
RU2794148C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| CONJUGATED IMMUNOGLOBULINS WITH C-TERMINAL LYSINE | 2016 |
|
RU2747581C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| PHARMACEUTICAL COMPOSITION OF FUSION PROTEIN TACI-FC | 2020 |
|
RU2779387C1 |
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS | 2012 |
|
RU2563346C2 |
